Talee Bio is developing a gene therapy for cystic fibrosis (CF), the first curative treatment for this disease. Talee has developed a novel transgene and a number of innovations in a well-characterized delivery vector that collectively will overcome challenges that have previously limited the clinical viability of gene therapy for CF. Rspresenting a collaboration among drug development professionals with more than 60 years of combined experience, and academic founders of the company, from the University of Iowa, who have been investigating CF pathogenesis and treatment, including gene therapy strategies, for more than 25 years.
